logo-loader

NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst

Last updated: 19:15 12 Jul 2023 BST, First published: 19:08 12 Jul 2023 BST

Proactive research analyst John Savin speaks to Thomas Warner after releasing a new report on NanoViricides (NYSE-A:NNVC), a development-stage company that is creating special-purpose nanomaterials for antiviral therapy.

Savin gives an overview of what the company does, as well as its current operations and its financial situation.

He highlights that NanoViricides is currently undertaking its first ever clinical trial, of an edible treatment for Covid-19 in India.

Click here to read the report

NanoViricides makes progress as it completes dosing in Phase 1a COVID study

Proactive research analyst John Savin speaks to Stephen Gunnion after publishing a research note about the latest Covid trial from development-stage antiviral company NanoViricides (NYSE-A:NNVC). The company has successfully completed dosing in a Phase 1a COVID study, marking a major...

on 29/1/24
OSZAR »